Tuberculosis Clinical Trial
Official title:
A Dose Selection Study Evaluating the Safety and Immunogenicity of 2 Different Doses of a New TB Vaccine, MVA85A, in Healthy Volunteers Who Have Previously Been Vaccinated With BCG
The dose of recombinant MVA used in the TB trials to date is relatively low compared with other trials using recombinant MVAs which have used up to 2.5 x 108pfu (A Hill, personal communication). Having demonstrated safety and immunogenicity of 5 x 107pfu of MVA85A, we now need to perform a dose optimization study, prior to commencing larger scale Phase II and III studies in South Africa. We will vaccinate 12 volunteers with a dose half a log lower than the dose we are currently using, i.e. 107pfu MVA85A, and 12 volunteers with a dose half a log higher, i.e. 108pfu.
MVA85A (at a dose of 5 x 107pfu) has been administered to 41 healthy volunteers in the UK
and 17 healthy volunteers in The Gambia, with no serious adverse events. We have designed
our Phase I studies to allow for a vaccination of volunteer groups sequentially with a
step-wise increase in mycobacterial exposure, in order to minimize the possibility of a Koch
reaction. A Koch reaction describes the development of immunopathology in a person or animal
with tuberculosis, when an exaggerated immune response to M.tb is stimulated. It was
described in patients with TB disease when Koch performed his original studies employing
mycobacteria as a type of therapeutic vaccination. It has now been demonstrated in the mouse
model of therapeutic vaccination (Taylor, 2003). Available animal data suggest that these
reactions do not occur in mice latently infected with M.tb, suggesting that such reactions
may correlate with high bacterial load and that the Koch phenomenon may not pose a problem
for vaccination of healthy albeit latently infected humans. We started these studies in
healthy volunteers who were as mycobacterially naïve as possible. They were skin test
negative and Elispot negative for PPD, ESAT 6 and CFP10, and had not had previously been
vaccinated with BCG. We have now completed studies in the UK vaccinating volunteers
previously vaccinated with BCG (McShane, 2004). These volunteers are excluded if their
Mantoux test is greater than 15 millimeters. These studies are ongoing in The Gambia. The
group we are currently recruiting for on this increasing mycobacterial spectrum are healthy
volunteers who are latently infected with M.tb.
Decision matrix for selecting MVA85A dose
1. If reducing the dose of MVA85A results in reduced immunogenicity, we could use either
the 5x107 or 108 dose, and would select the lower of these on the grounds of safety.
2. If increasing the dose of MVA85A increases the incidence of side-effects, we could use
either the 5x107 or 107 dose, and we would use the higher of these on the grounds of
immunogenicity.
3. If increasing the dose of MVA85A results in increased immunogenicity and no increase in
side-effects, we could use either the 5x107 or 108 dose in subsequent trials
4. If reducing the dose of MVA85A results in no reduction in immunogenicity we could use
either the 107 or 5x107 dose in subsequent trials
5. If all three doses are equally safe and immunogenic we will use either the low or 5x107
dose.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |